R. Joppi, V. Bertele, and S. Garattini, Orphan drug development is progressing too slowly, Br J Clin Pharmacol, vol.61, issue.3, pp.355-60, 2006.

C. Molster, Key outcomes from stakeholder workshops at a symposium to inform the development of an Australian national plan for rare diseases, Orphanet J Rare Dis, vol.7, p.50, 2012.

. Orphanet and . Orphanet, Report Series -List of rare diseases -listed in alphabetical number, 2012.

. Eurordis, Fact Sheet, 2007.

V. L. Colledge and J. Solly, The rare disease challenge and how to promote a productive rare disease community: Case study of Birt-Hogg-Dube Symposia, Orphanet J Rare Dis, vol.7, p.63, 2012.

C. Breithaupt, Contribution to the treatment of rare diseases: orphan drugs, J Eur Medical Writers Assoc Write Stuff, vol.18, issue.1, pp.21-24, 2009.

, EMA. Orphan Medicines Figures, 2000.

, Update, 2015.

, Current Results of Research, 2016.

, Guideline on clinical trials in small populations, CHMP, 2007.

, Concept paper on extrapolation of efficacy and safety in medicine development, EMA, 2012.

. Fda and . Rare, Diseases: Common Issues in Drug Development Guidance for Industry, 2015.

K. E. Karlsson, Benefits of pharmacometric model-based design and dnalysis of clinical trials, Acta Universitatis Upsaliensis, vol.133, 2010.

J. Barrett, Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and rranslational research settings, J Clin Pharmacol, vol.48, p.632, 2008.

T. Burzykowski, G. Molenberghs, and M. Buyse, The Evaluation of Surrogate Endpoints, 2005.

L. Frank, E. Basch, and J. V. Selby, The PCORI perspective on patient-centered outcomes research, J Am Med Assoc, vol.312, issue.15, pp.1513-1517, 2014.

E. Gargon, Choosing important health outcomes for comparative effectiveness research: a systematic review, PLoS One, vol.9, p.6, 2014.

T. J. Kiresuk and R. E. Sherman, Goal attainment scaling: A general method for evaluating comprehensive community mental health programs, Community Ment Health J, vol.4, issue.6, pp.443-53, 1968.

S. J. Pocock, N. L. Geller, and A. A. Tsiatis, The analysis of multiple endpoints in clinical trials, Biometrics, vol.43, issue.3, pp.487-98, 1987.

M. Posch and A. Futschik, A uniform improvement of Bonferroni-type tests by sequential tests, J Am Stat Assoc, vol.103, issue.481, pp.299-308, 2008.

F. Bretz, A graphical approach to sequentially rejective multiple test procedures, Stat Med, vol.28, issue.4, pp.586-604, 2009.

, European Organisation for Rare Diseases, 2016.

L. N. Kennes, The impact of selection bias on test decisions in randomized clinical trials, Stat Med, vol.30, issue.21, pp.2573-81, 2011.

F. Bretz, Adaptive designs for confirmatory clinical trials, Stat Med, vol.28, issue.8, pp.1181-217, 2009.

J. W. Gerss and W. Köppke, Clincal trials and rare diseases, Adv Exp Med Biol, vol.686, pp.173-90, 2010.

. Fda, Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials, 2016.

M. Wästfelt, B. Fadeel, and J. I. Henter, A journey of hope: lessons learned from studies on rare diseases and orphan drugs, J Intern Med, vol.260, issue.1, pp.1-10, 2006.

R. Van-der-graaf, K. C. Roes, and J. J. Van-delden, Adaptive trials in clinical research: scientific and ethical issues to consider, JAMA, vol.307, issue.22, pp.2379-80, 2012.

E. J. Emanuel, D. Wendler, and C. Grady, What makes clinical research ethical?, JAMA, vol.283, issue.20, pp.2701-2712, 2000.

S. Gupta, A framework for applying unfamiliar trial designs in studies of rare diseases, J Clin Epidemiol, vol.64, issue.10, pp.1085-94, 2011.

C. Cornu, Experimental designs for small randomized clinical trials: an algorithm for choice, Orphanet J Rare Dis, vol.8, p.48, 2013.